Cart
×
Self-Stretches for Duchenne
As part of CureDuchenne Cares – a physical therapy, education and outreach program for the Duchenne community – we are pleased to share information on a self-stretching routine for […]
Update on Phase 3 tadalafil DMD study: enrollment completed
CureDuchenne is pleased to share the following update to the Duchenne muscular dystrophy community from Lilly regarding the ongoing Phase 3 trial of tadalafil in boys with Duchenne. Eli Lilly […]
Keeping the Promise for our Children with Duchenne
Today, CureDuchenne announced a $1 million investment in Capricor Therapeutics for a clinical trial to test its CDC (adult) stem cells as a cardiac therapy for Duchenne patients. CureDuchenne’s mission […]
Sarepta Therapeutics Reports Long-Term Outcomes through 168 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy
Sarepta Therapeutics released the 168 week data for their exon skipping drug, eteplirsen, this morning. During a three year period, 7-13 year old boys with Duchenne (the age range of […]
Pfizer Initiates Phase 2 Study of PF-06252616 in Duchenne Muscular Dystrophy
Pfizer Inc. (NYSE:PFE) announced today enrollment of the first patient in a multicenter Phase II clinical trial of the investigational compound PF-06252616 in boys with Duchenne muscular dystrophy (DMD), a […]
Power Wheelchair Options for Duchenne Muscular Dystrophy Patients
Duchenne Therapy Network and CureDuchenne released their newest video blog that highlights power wheelchair options available for Duchenne muscular dystrophy patients. Here we provide tips on what to look […]
TACT TREAT–NMD Review
Last weekend, I had the honor, along with Dr. Mike Kelly, CureDuchenne’s Chief Scientific Officer, and other TACT members, to review Duchenne research projects. CureDuchenne was able to look […]
Adapting Physical Education for those Impacted with Duchenne
Those who live with Duchenne muscular dystrophy have physical activity limitations that need to be addressed at school. It is important for those impacted with Duchenne to be included without further […]
Eteplirsen Updates from the World Muscle Society Meeting
Sarepta provided an 144 week update on eteplirsen at the World Muscle Society meeting. Here are some brief notes. Neutral charge as it passes through kidney; cleared through kidney […]